ProfileGDS5678 / 1428715_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 84% 86% 88% 83% 83% 83% 85% 87% 85% 84% 88% 85% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.4195486
GSM967853U87-EV human glioblastoma xenograft - Control 26.2661984
GSM967854U87-EV human glioblastoma xenograft - Control 36.5389186
GSM967855U87-EV human glioblastoma xenograft - Control 47.1003888
GSM967856U87-EV human glioblastoma xenograft - Control 56.1139383
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.9207683
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9075383
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3706585
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.5828787
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3470985
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.1769884
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8388588
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.3130185
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1641984